Post a solid Q 2019 -- showing pembrolizumab is beating the BMS immuno-oncology agent, in sales revenue rather handily. Then, slip in a $1.2 billion charge, to (among other things) close facilities and pay severance to what? 600 to 1,000 workers (Merck hasn't said -- but that's my guess)? Who really knows. I get it -- but I don't like it (per Bloomberg, this morning):
. . . .Merck will close some plants and shed workers as part of a cost-cutting effort over the next several years. Because of the cuts, the company said it expects to take a charge of $800 million to $1.2 billion by the end of 2023. . . .
Onward, a little downbeat in truth, knowing that some fine science jobs are (once again) on the line.
नमस्ते
1 comment:
Speak freely, we were both up early a decade ago, at above.
It was... sublime!
Smile.
Post a Comment